[Click e-Stock] "Abion Confirms Vavamakep Clinical Results... Next-Generation iRAC Platform Boosts Oncology Drug Value"

There is analysis suggesting that Abion is enhancing its prospects for global technology transfer based on the clinical performance of its core new drug candidate, Vavamakep (ABN401), while also expanding its oncology pipeline by promoting the next-generation immuno-oncology platform, iRAC.

On July 29, Changyoon Park, a researcher at GL Research, presented in a report that the main investment points for Abion are the clinical competitiveness of Vavamakep and the expansion of the pipeline based on the next-generation immuno-oncology platform, iRAC.

Abion is a company developing anti-cancer drugs that advances a precision medicine strategy to improve the likelihood of successful treatment by leveraging patients' biomarkers based on companion diagnostic technology. The company is currently focusing on clinical development of Vavamakep, a treatment for MET exon 14 skipping non-small cell lung cancer, while broadening new drug development based on the iRAC platform and CLDN3-targeted antibodies. Abion is also promoting a 'Focus, Prove, Partner' strategy centered on global technology transfer.

The flagship pipeline Vavamakep presented global Phase 2 clinical results at the American Society of Clinical Oncology (ASCO) in 2026. The trial recorded an objective response rate (ORR) of 55% and a duration of response (DoR) of 14.5 months. In addition, the incidence rate of peripheral edema, a major side effect, was lower than that of competing drugs, confirming the potential for long-term administration.

The company plans to complete Phase 2 clinical trials in the fourth quarter of this year and pursue additional technology transfer. The researcher anticipated that as more clinical results accumulate, the global commercialization value will further increase.

As a next-generation growth engine, the iRAC platform is attracting attention. iRAC is a first-in-class immuno-oncology platform that combines antibodies with interferon beta (IFN-β), representing a new approach intended to overcome resistance and the limitations of response durability associated with existing antibody-drug conjugates (ADCs).

The lead candidate, ABN202, demonstrated excellent anti-tumor efficacy and potential for long-term immune memory in ADC-resistant models. Global technology transfer and joint development are currently being pursued alongside preclinical development.

In addition, the CLDN3-targeted antibody candidate, ABN501, is also enhancing commercialization potential through a global co-development agreement. The company is continuously increasing pipeline value through a platform strategy that allows expansion into various therapeutic technologies, including single antibodies, ADCs, bispecific antibodies, and iRAC.

Changyoon Park, a researcher at GL Research, stated, "Abion has demonstrated Vavamakep's clinical competitiveness and is now expanding its next-generation pipeline based on the iRAC platform and CLDN3 antibody. As clinical achievements and platform technologies converge, we expect to see full-scale global technology transfer and a rise in corporate value."

The clinical achievements of Vavamakep and the expansion of the next-generation iRAC platform are evaluated as key growth drivers that simultaneously enhance Abion's prospects for global technology transfer and the value of its oncology new drug pipeline.

This content was produced with the assistance of AI translation services.